CPMD Pengajuan SEC - CannaPharmaRX, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1081938

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CannaPharmaRX, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact
August 14, 2025	EX-4.8	FORBEARANCE AGREEMENT EXHIBIT 4.8 FORBEARANCE AGREEMENT This Forbearance Agreement (this "Agreement"), is dated June 30, 2025 (the "Effective Date"), is entered into among 2323414 Alberta Ltd., a Canadian company (the "Lessee"), CannaPharmaRX, Inc., a Delaware corporation (the "Guarantor"), and Formosa Mountain Ltd. (the "Lessor"). RECITALS A. Lessee and Lessor are parties to that certain Lease commencing as of January
May 16, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact
May 16, 2025	EX-4.4	Amendment No. 1 to Amended and Restated Secured Promissory Note; entered into with Koze Investments LLC and Amir Tal EXHIBIT 4.4 AMENDMENT NO. 1 TO AMENDED AND RESTATED SENIOR SECURED PROMISSORY NOTE Amendment No. 1 to Amended and Restated Senior Secured Promissory Note (this “Amendment”), dated as of November 22, 2024, among Cannapharmarx, Inc., (the “Borrower”) and Koze Investments LLC (the “Lender”). WHEREAS, the Borrower and the Lender have entered into an Amended and Restated Senior Secured Promissory Note,
May 16, 2025	EX-4.5	Amendment No. 1 to Amended and Restated Senior Secured Promissory Note; entered into with Koze Investments EXHIBIT 4.5 AMENDMENT NO. 1 TO AMENDED AND RESTATED SECURED PROMISSORY NOTE Amendment No. 1 to Amended and Restated Secured Promissory Note (this “Amendment”), dated effective as of November 22, 2024, among Cannapharmarx, Inc., (the “Borrower”) and Koze Investments LLC and Amir Tal (collectively, the “Lender”). WHEREAS, the Borrower and the Lender have entered into an Amended and Restated Secured
May 16, 2025	EX-4.7	Transfer of 2323414 Alberta Ltd. to Elliot Zemel dated March 17, 2025 EXHIBIT 4.7 STOCK POWER FOR VALUE RECEIVED, CannapharmaRX, Inc. hereby sells, assigns and transfers unto Elliot Zemel all of the equity, stock, or shares of any kind and form (collectively the "Shares") of 2323414 Alberta Ltd., a Canadian corporation (the "Company"), standing in its name on the books of the Company, and does hereby irrevocably constitute and appoint the CEO of the Company as attor
May 16, 2025	EX-4.3	Amended and Restated Lease dated January 1, 2025 EXHIBIT 4.3 AMENDED AND RESTATED LEASE BETWEEN Formosa Mountain Ltd. (the “Landlord”) AND 2323414 Alberta Ltd. (the “Tenant”) AND CannaPharmaRX Inc. (the “Indemnifier”) 1 THIS AMENDED AND RESTATED LEASE (this “Lease”), dated effective January 1, 2025, is made by the Landlord and the Tenant. WHEREAS, the parties entered into that certain Lease Agreement dated January 1, 2022 (the “Previous Lease”);
May 16, 2025	EX-4.1	Letter Agreement between the Company and Koze Investments, LLC amd Amir Tal regarding Allocation of Revenue from IMC Cannabis Transaction dated March 17, 2025 EXHIBIT 4.1 CannaPharmaRx, Inc. Suite 3600 888-3rd Street SW Calgary, ALB T2P 5C5 March 17, 2025 Koze Investments, LLC Amir Tal Via Electronic Mail Re: Allocation of Revenue from IMC Cannabis Transaction This letter agreement (this “Letter Agreement”) will confirm our understanding with respect to certain matters relating to the allocation of revenue by CannaPharmaRx, Inc., and its subsidiaries (c
May 16, 2025	NT 10-Q	OMB APPROVAL OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Expires: May 31, 2025 Estimated average burden Washington, D.
May 16, 2025	EX-4.2	Security And Royalty Agreement between the Company and Koze Investments, LLC dated March 17, 2025 EXHIBIT 4.2 SECURITY AND ROYALTY AGREEMENT This SECURITY AND ROYALTY AGREEMENT (this “Security Agreement”), dated March 17, 2025, is made and granted by 2323414 Alberta Ltd. (“Subsidiary”) and CannaPharmaRX, Inc., a Delaware corporation (the “Grantor”), in favor of Elliot Zemel, or his assigns (“Secured Party”). RECITALS A. The parties have entered into that certain Amended and Restated Lease date
May 16, 2025	EX-4.6	Secured Promissory Note dated February 26, 2025 EXHIBIT 4.6 SECURED PROMISSORY NOTE $3,000,000 Effective Date: February 26, 2025 FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, 2323414 Alberta Ltd (the "Borrower"), hereby unconditionally promises to pay to the order of Groestate Inc. or its assigns (the "Lender," and together with the Borrower, the "Parties"), the principal amount of THREE MILLION DOLLARS ($3,000,0
May 6, 2025	EX-99.1	CannapharmaRx Continues into New European Market with First Shipment Completed to Germany EXHIBIT 99.1 CannapharmaRx Continues into New European Market with First Shipment Completed to Germany CannaPharmaRX, Inc. (OTC PINK: CPMD), a future leader in cannabis cultivation, is pleased to share recent updates, including its latest cultivation activities and sales achievements. Successful Shipments to Israel and Germany To date, the Company has successfully completed four shipments to Israe
May 6, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): [DATE] CannapharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission File Number
April 10, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact n
April 10, 2025	EX-19.1	Insider Trading Policy (Code of Ethics) EXHIBIT 19.1 POLICY ON INSIDER TRADING CANNAPHARMARX, INC. GENERAL PURPOSE U.S. Federal securities laws prohibit: (i) the purchase or sale of securities by persons who are aware of material nonpublic information about a company, as well as (ii) the disclosure to others of material, nonpublic information about a company who then trade in the company’s securities. These transactions are commonly kno
April 10, 2025	EX-4.1	Description of Common Stock EXHIBIT 4.1 DESCRIPTION OF COMMON STOCK The following description summarizes the most important terms of our publicly traded (OTCMKTS: CPMD) common stock. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are incorporated by reference as exhibits to this annual report, and to the applicable provisions of Delaware law. Common stock
April 10, 2025	EX-3.3	Certificate of Designation of Preferences, Rights and Limitation of Series C Convertible Preferred Stock EXHIBIT 3.3
April 10, 2025	EX-10.4	Lease agreement between CannaPharmaRX, Inc. and Formosa Mountain Ltd. dated January 1, 2022. EXHIBIT 10.4
April 1, 2025	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 333-251016 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report
March 31, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission Fil
December 3, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2024 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission
November 21, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission
November 21, 2024	EX-99.1	November 20, 2024 EXHIBIT 99.1 November 20, 2024 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read CannaPharmaRX, Inc.’s statements included under Item 4.01 of its Form 8-K dated November 20, 2024. We agree with the statements concerning our Firm under Item 4.01. We are not in a position to agree or disagree with other stat
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-27055 CANNAPHARMARX, INC. (E
September 17, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-27055 CANNAPHAR
June 25, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-27055 CANNAPHA
May 16, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-27055 CANNAPHARM
May 15, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 001-40409 CUSIP Number 39878L 308 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit
March 27, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 001-40409 CUSIP Number 39878L 308 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran
February 22, 2024	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorpo
February 22, 2024	EX-99.1	CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek Exhibit 99.1 CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek CALGARY, AB / ACCESSWIRE / February 15, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has entered into a strategic Supply Agreement (the "Agreement") with Cantek Holdings ("Cantek"), one of Israel's lead
February 22, 2024	EX-1.1	Supply Agreement between CannaPharmaRX, Inc. and D.N.S. Cantek 2019 Ltd dated February 12, 2024 Exhibit 1.1 SUPPLY AGREEMENT This Supply Agreement, dated as of February 12th, 2024 (the “Agreement”), is entered into by and between CannaPharmaRX, Inc., a Delaware corporation (“Supplier”), and D.N.S. CANTEK 2019 LTD, an Israeli limited corporation, or its Affiliates and assigns (“Buyer”, and together with Supplier, the “Parties”, and each, a “Party”). WHEREAS, Supplier is in the business of man
February 16, 2024	8-K	Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission
February 16, 2024	EX-1.1	Supply Agreement between CannaPharmaRX, Inc. and D.N.S. Cantek 2019 Ltd dated February 12, 2024 Exhibit 1.1 CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek CALGARY, AB / ACCESSWIRE / February 15, 2024 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has entered into a strategic Supply Agreement (the "Agreement") with Cantek Holdings ("Cantek"), one of Israel's leade
December 6, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission
December 6, 2023	EX-2.1	Amended and Restated Membership Interest Purchase Agreement, dated November 22, 2023 Exhibit 2.1 Execution Version AMENDED AND RESTATED MEMBERSHIP INTERESTS PURCHASE AGREEMENT between KOZE INVESTMENTS, LLC and AMIR TAL (“Sellers”) ELLIOT ZEMEL As “Sellers’ Representative” and CANNAPHARMARX, INC. (“Buyer”) AMENDED AND RESTATED MEMBERSHIP INTERESTS PURCHASE AGREEMENT This Amended and Restated Membership Interests Purchase Agreement (this "Agreement"), dated November 22, 2023, to be
November 17, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-251016 CAN
November 14, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 001-40409 CUSIP Number 39878L 308 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 CannaPharmaRX, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission F
November 13, 2023	EX-9.02	Engagement Letter with GreenGrowth CPAs dated November 3, 2023 Exhibit 9.02 CannaPharmaRx Inc. Audit Engagement Letter Thank you for choosing GreenGrowth CPAs (“we” or “our”) to provide audit services as described below (“Services”) for CannaPharmaRx Inc. (“Client”) shown and signed at the end of this Engagement Letter (“Engagement Letter”). This Engagement Letter describes the scope of GreenGrowth CPAs Services, the respective responsibilities of GreenGrowth
November 13, 2023	EX-9.01	Letter from BF Borgers CPA PC, dated November 13, 2023 Exhibit 9.01 5400 W Cedar Ave Lakewood, CO 80226 Telephone: 303.953.1454 Fax: 303.945.7991 November 13, 2023 United States Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, D.C. 20549 Re: CannaPharmaRX, Inc. Ladies and Gentleman: We have read the statements under item 4.01 in the Form 8-K dated November 6, 2023, of CannaPharmaRX, Inc. (the “Company”)
October 13, 2023	EX-9.01	Engagement Letter between CannaPharmaRX, Inc. and Invictus Accounting Group LLP (Oliver Foeste) dated July 25, 2023 Exhibit 9.1 July 25, 2023 Mr. Dean Medwid Chief Executive Officer CannaPharmaRX Inc. 3600 888 3rd Street SW Calgary, AB T2P 5C5 Re: CFO and Accounting Advisory Services - 2023 Dear Mr. Medwid: Introduction The purpose of this engagement letter (the "Agreement"), together with the Standard Terms and Conditions attached hereto, is to confirm our understanding of the terms of our engagement to provid
October 13, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission Fi
October 13, 2023	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCH Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 333-251016 CANNAPHARMARX, INC. (Exact name of small business issu
September 22, 2023	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXC Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 333-251016 CANNAPHARMARX, INC. (Exact name of small business iss
September 1, 2023	EX-10.6	CPMD May 25, 2023 Master Note Exhibit 10.6 MASTER PROMI SSO RY NOTE $2,000.000 USD Effect iv e Dat e: May 25, 2023 FOR VA L UE RECEIVED, and subject to the terms and cond ition s set forth herein, CannaPharmaRX (the "Borrower"), hereby unconditionally promises to pay to the o rder of Koze I nvestments, LLC or its assigns (the " Lender , " and together w i th the Borrower, the " Parti es") . the principal amount of TWO MILLION
September 1, 2023	10-K	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED: December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 333-251016 CANNAPHARMA
August 28, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission Fil
August 28, 2023	EX-99.1	CannaPharmaRx Expands Board of Directors Exhibit 99.1 CannaPharmaRx Expands Board of Directors CALGARY, AB / ACCESSWIRE / AUGUST 25, 2023 / CannaPharmaRx, Inc. (OTC EXPERT: CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has expanded its Board of Directors from three seats to five. The Board deemed this expansion was in the best interest of the Corporation as it coincides wit
June 23, 2023	EX-10.1	Employment Agreement between CannaPharmaRX, Inc. and 1082900 BC Ltd. (Dean Medwid) dated May 22, 2023 Exhibit 10.1 CannaPharmaRx Appoints Dean Medwid as New CEO CALGARY, AB / ACCESSWIRE / June 23, 2023 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 CannaPharmaRX, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 CannaPharmaRX, Inc. (Exact name of registrant as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commission File
March 30, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 001-40409 CUSIP Number 39878L 308 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran
November 21, 2022	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 333-251016 CANNAPHARMARX, INC. (Exact name of small business
November 14, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 001-40409 CUSIP Number 39878L 308 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra
October 4, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
August 26, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
August 22, 2022	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCH Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 333-251016 CANNAPHARMARX, INC. (Exact name of small business issu
August 12, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 001-40409 CUSIP Number 39878L 308 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti
August 11, 2022	424B3	435,951,370 Shares Common Stock 424B3 1 cannapharmarx424b3.htm FORM 424(B)(3) Filed pursuant to Rule 424(b)(3) Registration No.: 333-266457 435,951,370 Shares Common Stock This prospectus relates to the sale of up to 435,951,370 shares of our common stock by TYSADCO PARTNERS, LLC. The shares of our common stock to which this prospectus relates have been or may be issued by CANNAPHARMARX, INC. pursuant to a purchase agreement, da
August 9, 2022	S-1/A	As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	EX-10.1	Purchase Agreement by and between CannaPharmaRX, Inc. and Tysadco Partners, LLC, dated as of April 28, 2022 Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the "Agreement"), dated as of April 28, 2022, is entered into by and between CANNAPHARMARX, INC., a Delaware corporation (the "Company"), and TYSADCO PARTNERS, LLC, a Delaware limited liability company (the "Investor"). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and t
August 9, 2022	EX-10.3	Securities Purchase Agreement by and between CannaPharmaRX, Inc. and Tysadco Partners, LLC, dated as of April 28, 2022 Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of April 28, 2022, is entered into by and between CannaPharmaRx, Inc., a Delaware corporation, (the "Company"), and Tysadco Partners, LLC, a Delaware limited liability company (the "Buyer"). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemptio
August 9, 2022	EX-10.2	Registration Rights Agreement by and between CannaPharmaRX, Inc. and Tysadco Partners, LLC, dated as of April 28, 2022 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of April 28, 2022, by and between CANNAPHARMRX, INC., a Delaware corporation (the "Company"), and TYSADCO PARTNERS, LLC, a Delaware limited liability company (together with it permitted assigns, the "Buyer"). Capitalized terms used herein and not otherwise defined herein shall have the respec
August 9, 2022	RW	August 9, 2022 August 9, 2022 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: CannaPharmaRX, Inc. (the ?Company?) Registration Statement on Form S-1/A, File No. 333-251016 Request for Withdrawal Ladies and Gentleman: The Company hereby applies for withdrawal of the Company?s Amended Registration Statement (File No. 333-251016) containing exhibits only on Form S-1/A subm
August 8, 2022	EX-10.1	Purchase Agreement by and between CannaPharmaRX, Inc. and Tysadco Partners, LLC, dated as of April 28, 2022 Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the "Agreement"), dated as of April 28, 2022, is entered into by and between CANNAPHARMARX, INC., a Delaware corporation (the "Company"), and TYSADCO PARTNERS, LLC, a Delaware limited liability company (the "Investor"). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and t
August 8, 2022	EX-10.3	Securities Purchase Agreement by and between CannaPharmaRX, Inc. and Tysadco Partners, LLC, dated as of April 28, 2022 Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of April 28, 2022, is entered into by and between CannaPharmaRx, Inc., a Delaware corporation, (the "Company"), and Tysadco Partners, LLC, a Delaware limited liability company (the "Buyer"). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemptio
August 8, 2022	S-1/A	As filed with the Securities and Exchange Commission on August 1, 2022 As filed with the Securities and Exchange Commission on August 1, 2022 Registration No.
August 8, 2022	EX-10.2	Registration Rights Agreement by and between CannaPharmaRX, Inc. and Tysadco Partners, LLC, dated as of April 28, 2022 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of April 28, 2022, by and between CANNAPHARMRX, INC., a Delaware corporation (the "Company"), and TYSADCO PARTNERS, LLC, a Delaware limited liability company (together with it permitted assigns, the "Buyer"). Capitalized terms used herein and not otherwise defined herein shall have the respec
August 8, 2022	CORRESP	REQUEST FOR ACCELERATION OF EFFECTIVENESS August 8, 2022 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
August 1, 2022	S-1	As filed with the Securities and Exchange Commission on August 1, 2022. Registration No. 333-251016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 CANNAPHARMARX Table of Contents As filed with the Securities and Exchange Commission on August 1, 2022.
August 1, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price Amount of Registration Fee (3) Common Stock, $$0.
May 23, 2022	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXC Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 333-251016 CANNAPHARMARX, INC. (Exact name of small business iss
May 16, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 10-Q 1 cannapharmaext.htm EXTENSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 001-40409 CUSIP Number 39878L 308 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ T
April 15, 2022	10-K	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2021 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 333-251016 CANNAPHARMAR
March 31, 2022	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 001-40409 CUSIP Number 39878L 308 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Tran
February 16, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 333-251016 27-4635140 (State or other jurisdiction of incorporation) (Commissio
February 16, 2022	EX-99.6	CannaPharmaRx Acquiring Oklahoma Cannabis Facility Exhibit 99.6 CannaPharmaRx Acquiring Oklahoma Cannabis Facility CALGARY, AB / ACCESSWIRE / February 10, 2022 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has signed a Letter of Intent (LOI) to purchase an operating Cannabis facility located in Braman, Oklahoma. The property consists of 35,000 square f
November 15, 2021	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 ☒ Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period end Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 ? Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transact
August 16, 2021	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 ☒ Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period end Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 ? Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transaction p
July 16, 2021	EX-99.1	CannaPharmaRX, Inc. Closes Sale of Hanover Facility for $2,000,000 CAD Exhibit 99.1 CannaPharmaRX, Inc. Closes Sale of Hanover Facility for $2,000,000 CAD CALGARY, AB / ACCESSWIRE / July 13, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced today the sale of its Hanover, Ontario facility for $2,000,000 CAD. The Hanover facility includes ten acres of land and 48,800 square f
July 16, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 333-256123 24-4635140 (State or other jurisdiction of incorporation) (Commission Fi
June 22, 2021	EX-10.5	Consulting and Broker Agreement Exhibit 10.5 Consulting and Broker Agreement This Consulting and Broker Agreement (hereinafter the "Agreement") is made this 19th day of May, 2021 (the "Effective Date"), by and between K&K Consultants Ltd., of 144 A Menachem Begin Rd. Tel-Aviv 6492124, Israel (hereinafter referred to as "K&K") and CannapharmaRx Inc. and their subsidiaries and affiliates (hereinafter referred to as "Client"). WHER
June 22, 2021	EX-99.6	CannaPharmaRX, Inc. Signs Agreement with Israeli Group K&K Consulting Exhibit 99.6 CannaPharmaRX, Inc. Signs Agreement with Israeli Group K&K Consulting Agreement Provides Exposure to Israeli Medicinal Cannabis Market CALGARY, AB / ACCESSWIRE / June 16, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced today it has formally executed an agreement with K&K Consulting to broa
June 22, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 333-256123 24-4635140 (State or other jurisdiction of incorporation) (Commission Fi
June 10, 2021	424B3	PROSPECTUS CannaPharmaRx, Inc. 125,000,000 SHARES OF COMMON STOCK Filed pursuant to Rule 424(b)(3) Registration No. 333-256123 PROSPECTUS CannaPharmaRx, Inc. 125,000,000 SHARES OF COMMON STOCK This prospectus relates to the resale of shares of our Common stock, par value $0.0001 per share (the ?Common Stock?), of an aggregate of 125,000,000 Common Stock Shares as follows: (a) up to 125,000,000 Common Stock Shares to holders of the Series A Preferred Stock shares
June 9, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 333-251016 24-4635140 (State or other jurisdiction of incorporation) (Commission Fil
June 9, 2021	CORRESP	REQUEST FOR ACCELERATION OF EFFECTIVENESS June 9, 2021 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
June 9, 2021	EX-99.6	CannaPharmaRX, Inc. Sells Hanover Facility for $2,000,000 CAD Exhibit 99.6 CannaPharmaRX, Inc. Sells Hanover Facility for $2,000,000 CAD CALGARY, AB / ACCESSWIRE / June 8, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced today it is selling its Hanover, Ontario facility for $2,000,000 CAD. The Hanover facility includes ten acres of land and 48,800 square feet of g
June 9, 2021	EX-10.5	Purchase and Sale Agreement and the Amendment to the Purchase and Sale Agreement with Just in Time Capital, Inc. Exhibit 10.5 AMENDMENT OF AGREEMENT OF PURCHASE AND SALE This Amending Agreement (this ?Amendment?) dated as of the 1st day of June, 2021 (the "Effective Date"), is entered into BETWEEN: ALTERNATIVE MEDICAL SOLUTIONS INC. (hereinafter referred to as the "Vendor") AND: JUST IN TIME CAPITAL INC. (hereinafter referred to as the "Purchaser") WHEREAS by an agreement of purchase and sale dated December
May 26, 2021	CORRESP	Joshua D. Brinen CORRESP 1 filename1.htm Joshua D. Brinen Attorney at Law New York Office [email protected] Member New York, New Jersey, Florida, California, Texas & Nevada Bar LL.M. in Taxation May 26, 2021 VIA EDGAR ELECTRONIC FILING ONLY United States Securities and Exchange Commission Washington, D.C. 20549 Division of Corporation Finance Attn: Jeffrey Gabor, Esq. Re: CannaPharmaRx, Inc. (the “Issuer”) Pos
May 26, 2021	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Delaware 2834 27-4635140 (State of Incorporation) (PSIC Number) (IRS EIN) 888 ? 3rd Street SW Suite 3600 Calgary, Alberta, CanadaT2P 5C5 949-652-6838 Please send copies of all communications to: CannaPharmaRx, Inc. 888 ? 3r
May 17, 2021	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2021 Commission File Number: 333-251016 CANNAPHARMARX, INC. (Exact name of small business Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2021 Commission File Number: 333-251016 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) Suite
May 14, 2021	S-1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Delaware 2834 27-4635140 (State of Incorporation) (PSIC Number) (IRS EIN) 888 ? 3rd Street SW Suite 3600 Calgary, Alberta, CanadaT2P 5C5 949-652-6838 Please send copies of all communications to: CannaPharmaRx, Inc. 888 ? 3rd
May 3, 2021	POS AM	- POS AM Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT No. 3 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Delaware 2834 27-4635140 (State of Incorporation) (PSIC Number) (IRS EIN) 888 ? 3rd Street SW Suite 3600 Calgary, Alberta, CanadaT2P 5C5 949-652-6838 Please send copies of all communications t
April 28, 2021	CORRESP	April 27, 2021 April 27, 2021 VIA EDGAR ELECTRONIC FILING ONLY United States Securities and Exchange Commission Washington, D.
April 21, 2021	CORRESP	Joshua D. Brinen Joshua D. Brinen Attorney at Law New York Office [email protected] Member New York, New Jersey, Florida, California, Texas & Nevada Bar LL.M. in Taxation April 20, 2021 VIA EDGAR ELECTRONIC FILING ONLY United States Securities and Exchange Commission Washington, D.C. 20549 Division of Corporation Finance Attn: Jeffrey Gabor, Esq. Re: CannaPharmaRx, Inc. (the ?Issuer?) Post-Effective Amendment
April 21, 2021	EX-4.2	Stock Purchase Agreement with Silverback Capital Corporation Exhibit 10.9 STOCK PURCHASE AGREEMENT Common Stock Shares in Cannapharmarx Inc sold by Cannapharmarx Inc. To Silverback Capital Corporation THE SECURITIES OFFERED HEREBY ARE SPECULATIVE AND INVOLVE A HIGH DEGREE OF RISK AND SHOULD NOT BE PURCHASED BY ANYONE WHO CANNOT AFFORD THE LOSS OF HIS/HER ENTIRE INVESTMENT. This Stock Purchase Agreement (this ?Agreement?) is made effective on April 6, 2021 b
April 21, 2021	EX-4.1	Stock Purchase Agreement with BHP Capital, NY, Inc. Exhibit 10.8 STOCK PURCHASE AGREEMENT Common Stock Shares in Cannapharmarx Inc sold by Cannapharmarx Inc. To BHP Capital NY, Inc. THE SECURITIES OFFERED HEREBY ARE SPECULATIVE AND INVOLVE A HIGH DEGREE OF RISK AND SHOULD NOT BE PURCHASED BY ANYONE WHO CANNOT AFFORD THE LOSS OF HIS/HER ENTIRE INVESTMENT. SEE ?RISK FACTORS.? THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED WITH OR APPROVED OR
April 21, 2021	POS AM	- POS AM 2 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT No. 2 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Delaware 2834 27-4635140 (State of Incorporation) (PSIC Number) (IRS EIN) 888 ? 3rd Street SW Suite 3600 Calgary, Alberta, CanadaT2P 5C5 949-652-6838 Please send copies of all communications t
April 15, 2021	POS AM	- POST EFFECTIVE AMENDMENT NO. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT No. 1 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Delaware 2834 27-4635140 (State of Incorporation) (PSIC Number) (IRS EIN) 888 ? 3rd Street SW Suite 3600 Calgary, Alberta, CanadaT2P 5C5 949-652-6838 Please send copies of all communications t
April 14, 2021	10-K	Annual Report - ANNUAL REPORT Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 333-251016 CANNAPHARMAR
April 1, 2021	NT 10-K	- 10-K EXTENSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: December 31, 2020 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Peri
January 28, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 CannaPharmaRx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 333-251016 24-4635140 (State or other jurisdiction of incorporation) (Commission
January 28, 2021	EX-99.1	CannaPharmaRx, Inc. Announces the Acceptance of its Offer to Purchase Assets and Facilities Located in Saskatoon, Saskatchewan Purchase is financed through non-dilutive funding Represents the second facility contracted for purchase by CannaPharmaRx i Exhibit 99.1 CannaPharmaRx, Inc. Announces the Acceptance of its Offer to Purchase Assets and Facilities Located in Saskatoon, Saskatchewan Purchase is financed through non-dilutive funding Represents the second facility contracted for purchase by CannaPharmaRx in 2021 for combined manufacturing and cultivation of over 152,200 square feet. Combined production capability of 9,200 kilograms of canna
January 22, 2021	EX-99.1	555 Fifth Avenue, Suite 302, New York, NY 10017 Phone: 212 658 1019 • e-mail [email protected] Exhibit 99.1 December 23, 2020 [email protected] CannaPharmaRX Inc. 888-3rd Street SW, Suite 3600 Calgary, Alberta, Canada T2P 5C5 Attention: Nick Colvin Subject: First Mortgage Loan, 1 Plant Technology Rd, Saskatoon, Saskatchewan Canada and PO Box 209 Cremona, Alberta Canada Dear Mr. Colvin, We are pleased to inform you that we will commit to referenced project to fund Twelve Million Doll
January 22, 2021	EX-99.2	CannapharmaRx, Inc. Announces Non-Dilutive Commitment Financing for Assets and Facilities Located in Cremona, AB Exhibit 99.2 CannapharmaRx, Inc. Announces Non-Dilutive Commitment Financing for Assets and Facilities Located in Cremona, AB CALGARY, AB / ACCESSWIRE / January 19, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD) a future leader in ultramodern, highly efficient cannabis production facilities in Canada announced today that it has secured a commitment letter for twelve million dollars ($12,000,000) for t
January 22, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2021 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission
January 20, 2021	424B3	PROSPECTUS CannaPharmaRx, Inc. 22,017,682 SHARES OF COMMON STOCK 424B3 1 canna424b3.htm PROSPECTUS Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-251016 PROSPECTUS CannaPharmaRx, Inc. 22,017,682 SHARES OF COMMON STOCK This prospectus relates to the resale of shares of our Common stock, par value $0.0001 per share (the “Common Stock”), of an aggregate of 22,017,682 Common Stock Shares pursuant to our October 21, 2020 Common Stock Purchas
January 19, 2021	CORRESP	- January 19, 2021 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
January 15, 2021	S-1/A	- FORM S-1 AMENDMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Delaware 2834 27-4635140 (State of Incorporation) (PSIC Number) (IRS EIN) 888 – 3rd Street SW Suite 3600 Calgary, Alberta, CanadaT2P 5C5 949-652-6838 Please send copies of all communications to: CannaPharmaRx, Inc. 888 – 3r
January 12, 2021	EX-99.1	CannapharmaRx, Inc. Announces the Acceptance of its Offer to Purchase Assets and Facilities Located in Cremona AB Exhibit 99.1 CannapharmaRx, Inc. Announces the Acceptance of its Offer to Purchase Assets and Facilities Located in Cremona AB CALGARY, AB / ACCESSWIRE / January 12, 2021 / CannapharmaRx, Inc. (OTC PINK:CPMD) a future leader in ultramodern, highly efficient cannabis production facilities in Canada announced today that it has entered into a definitive agreement to purchase certain assets including
January 12, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission
December 18, 2020	S-1/A	- FORM S-1 AMENDMENT 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Delaware 2834 27-4635140 (State of Incorporation) (PSIC Number) (IRS EIN) 888 – 3rd Street SW Suite 3600 Calgary, Alberta, CanadaT2P 5C5 949-652-6838 Please send copies of all communications to: CannaPharmaRx, Inc. 888 – 3r
December 18, 2020	CORRESP	- December 18, 2020 VIA EDGAR ELECTRONIC FILING ONLY United States Securities and Exchange Commission Washington, D.
December 2, 2020	DEL AM	- DELAY REQUEST December 2, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 27, 2020	S-1	Registration Statement - REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CannaPharmaRx, Inc. Delaware 2834 27-4635140 (State of Incorporation) (PSIC Number) (IRS EIN) 888 – 3rd Street SW Suite 3600 Calgary, Alberta, CanadaT2P 5C5 949-652-6838 Please send copies of all communications to: CannaPharmaRx, Inc. 888 – 3rd
November 12, 2020	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: September 30, 2020 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small busin Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: September 30, 2020 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) Sui
August 20, 2020	EX-99.6	CannaPharmaRx Secures $3 Million Investment to Accelerate Expansion Exhibit 99.6 CannaPharmaRx Secures $3 Million Investment to Accelerate Expansion CALGARY, AB / ACCESSWIRE / August 17, 2020 / CannaPharmaRx, Inc. (OTC PINK:CPMD) a future leader in ultramodern, highly efficient cannabis production facilities in Canada, today announced it has secured up to a $3 million investment from Triton Funds.. Triton Funds, coupled with the support of of its advisory board an
August 20, 2020	EX-10.5	Stock Purchase Agreement Exhibit 10.5 COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”), dated as of August 10, 2020 (the “Execution Date”), is entered into by and between Cannapharmarx Inc., a Delaware corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”). RECITALS: WHEREAS, upon the terms and subject to the conditions contained herein, the
August 20, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2020 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission F
August 19, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: June 30, 2020 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) Suite 36
August 14, 2020	NT 10-Q	- NOTICE OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period E
July 6, 2020	EX-10.5	Purchase Agreement with Bristol Capital Investors LLC Exhibit 10.5 LIMITED LIABILITY COMPANY MEMBERSHIP INTEREST PURCHASE AGREEMENT by and between BRISTOL CAPITAL INVESTORS, LLC a Delaware limited liability company as Seller and CANNAPHARMARX INC. a Delaware corporation as Buyer Dated as of June 24, 2020 Table of Contents ARTICLE I. DEFINITIONS AND USAGE 1 Section 1.01 Definitions 1 Section 1.02 Usage 5 ARTICLE II. SALE AND TRANSFER OF RRPC INTEREST;
July 6, 2020	EX-99.1	CANNAPHARMARX AGREES TO ACQUIRE CA CANNABIS FACILITY Company Agrees to Purchase River Road Production Campus from Bristol Capital Investors Exhibit 99.1 For Immediate Release July 6, 2020 CANNAPHARMARX AGREES TO ACQUIRE CA CANNABIS FACILITY Company Agrees to Purchase River Road Production Campus from Bristol Capital Investors CALGARY, AB / ACCESSWIRE / July 6, 2020 / CannaPharmaRx, Inc. (OTC PINK:CPMD) a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced today it has signed a letter of i
July 6, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission Fil
June 29, 2020	10-Q	Quarterly Report - QUARTERLY REPORT Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2020 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) Suite 3
June 29, 2020	DEF 14A	Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 filed on June 29, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [ ] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [] Definitive Additional Materials [] Soliciting Material under Rule 14a-12 Cannapharmarx, Inc.
June 22, 2020	10-K/A	Annual Report - AMENDMENT NO. 1 Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 000-2
June 10, 2020	8-K	Regulation FD Disclosure, Termination of a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2020 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission File
June 10, 2020	EX-99.1	Sale of Sunniva Medical to CannapharmaRx is Terminated CannapharmaRx turns its attention to acquiring a revenue producing property Exhibit 99.1 For Immediate Release June 10, 2020 Sale of Sunniva Medical to CannapharmaRx is Terminated CannapharmaRx turns its attention to acquiring a revenue producing property Calgary, Alberta, June 10, 2020 - CannaPharmaRx, Inc. (OTC Pink Sheets: “CPMD”) a future leader in ultramodern, highly efficient cannabis production facilities in Canada and the US, announced today that the Company has b
May 27, 2020	10-K	Annual Report - ANNUAL REPORT Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 000-27055 CANNAPHARMARX
May 20, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 9U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission Fil
May 20, 2020	EX-99.7	CANNAPHARMARX, INC. ISSUES LETTER TO SHAREHOLDERS Exhibit 99.7 CANNAPHARMARX, INC. ISSUES LETTER TO SHAREHOLDERS Calgary, AB – May 13, 2020 – CannaPharmaRx, Inc. (OTC Pink: CPMD) today issued a letter from its Chief Executive Officer, Dominic Colvin. Dear Fellow Shareholders: Let me start off by saying that I hope this letter finds all of you safe and healthy. In these uncertain times, I wanted to reach out to reassure you that we are continuing
May 14, 2020	NT 10-K	- EXTENSION FOR 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Peri
May 14, 2020	8-K	Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission File
March 27, 2020	8-K	Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2020 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission Fi
March 17, 2020	EX-10.6	Amendment No 3 to Securities Purchase Agreement with Sunniva Inc. Exhibit 10.6 AMENDING AgREEMENT No. 3 TO SHARE PURCHASE AGREEMENT This Amending Agreement No. 3 to the Share Purchase Agreement is dated March 16, 2020 (the “Amending Agreement No. 3”) by and among CannaPharmaRx Canada Corp. (the “Purchaser”), CannaPharmaRx, Inc. (the “Purchaser Parent”) and Sunniva Inc. (the “Vendor”). WHEREAS, the Purchaser, the Purchaser Parent and the Vendor entered into a Sha
March 17, 2020	EX-99.1	SUNNIVA INC. ANNOUNCES AMENDED TERMS OF THE PREVIOUSLY ANNOUNCED SALE OF SUNNIVA MEDICAL INC. TO CANNAPHARMARX, INC. Exhibit 99.1 For Immediate Release March 17, 2020 SUNNIVA INC. ANNOUNCES AMENDED TERMS OF THE PREVIOUSLY ANNOUNCED SALE OF SUNNIVA MEDICAL INC. TO CANNAPHARMARX, INC. VANCOUVER and KELOWNA, BC – March 17, 2020 – Sunniva Inc. (“Sunniva”, the “Company”, “we”, or “our”) (CSE:SNN, OTCQB:SNNVF) and CannaPharmaRx Canada Corp. (“CannaPharmaRx”), a subsidiary of CannaPharmaRx, Inc. (OTC Pink: CPMD) announ
March 17, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2020 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission Fi
February 10, 2020	EX-4.1	Form of the Notes Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T
February 10, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2020 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission
February 10, 2020	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 8, 2020, by and between CANNAPHARMARX, INC., a Delaware corporation, with headquarters located at 3600 888-3rd St. SW, Calgary, Alberta, Canada T2P5C5 (the “Company”), and INVESTOR, a Delaware limited liability company, with its address at INVESTOR’S ADDRESS (the “Buyer”). WHEREAS:
February 7, 2020	EX-10.5	Amendment to Securities Purchase Agreement with Sunniva Inc. Exhibit 10.5 AMENDING AGREEMENT NO. 2 TO SHARE PURCHASE AGREEMENT This Amending Agreement No. 2 to the Share Purchase Agreement is dated November 27, 2019 (the “Amending Agreement No. 2”) by and among CannaPharmaRx Canada Corp. (the “Purchaser”), CannaPharmaRx, Inc. (the “Purchaser Parent”) and Sunniva Inc. (the “Vendor”). WHEREAS, the Purchaser, the Purchaser Parent and the Vendor entered into th
February 7, 2020	EX-99.6	Sunniva Inc. And CannaPharmaRx, Inc. Announce Extension To Outside Date Of Share Purchase Agreement For Sale Of Sunniva Medical Inc. Exhibit 99.6 November 28, 2019 Sunniva Inc. And CannaPharmaRx, Inc. Announce Extension To Outside Date Of Share Purchase Agreement For Sale Of Sunniva Medical Inc. KELOWNA, British Columbia and VANCOUVER, British Columbia, Nov. 28, 2019 /CNW/ - Sunniva Inc. ("Sunniva", the "Company", "we", "our" or "us") (CSE:SNN, OTCQB:SNNVF) and CannaPharmaRx Canada Corp. ("CannaPharmaRx"), a subsidiary of Canna
February 7, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2019 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission
December 3, 2019	10-K/A	CPMD / Cannapharmarx Inc. 10-K/A - Annual Report - FORM 10-K/A AMENDMENT 2 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact na
November 20, 2019	10-Q/A	CPMD / Cannapharmarx Inc. 10-Q/A - Quarterly Report - FORM 10-Q AMENDMENT NO. 1 Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q/A Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: June 30, 2019 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State or other jurisdiction of incorporation) (IRS Employer ID No.) 3600 8
November 20, 2019	10-Q/A	CPMD / Cannapharmarx Inc. 10-Q/A - Quarterly Report - FORM 10-Q AMENDMENT NO. 1 Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q/A Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2019 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) Suite
November 14, 2019	10-Q	CPMD / Cannapharmarx Inc. 10-Q - Quarterly Report - FORM 10-Q Tables of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: September 30, 2019 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State or other jurisdiction of incorporation) (IRS Employer ID No.) 36
October 3, 2019	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2019 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission F
October 3, 2019	EX-99.6	SUNNIVA INC. ANNOUNCES AMENDED TERMS OF THE PREVIOUSLY ANNOUNCED SALE OF SUNNIVA MEDICAL INC. TO CANNAPHARMARX AND REVISED CLOSING DATE FOR THE SECOND TRANCHE OF USD $7,500,000 DEBT FINANCING Not for Dissemination in the United States or for Distribu Exhibit 99.6 For Immediate Release October 3, 2019 SUNNIVA INC. ANNOUNCES AMENDED TERMS OF THE PREVIOUSLY ANNOUNCED SALE OF SUNNIVA MEDICAL INC. TO CANNAPHARMARX AND REVISED CLOSING DATE FOR THE SECOND TRANCHE OF USD $7,500,000 DEBT FINANCING Not for Dissemination in the United States or for Distribution to U.S. Newswire Services VANCOUVER, BC – October 3, 2019 – Sunniva Inc. (“Sunniva”, the “Comp
October 3, 2019	EX-10.5	Amendment to Securities Purchase Agreement with Sunniva Inc. Exhibit 10.5 AMENDING AGREEMENT TO SHARE PURCHASE AGREEMENT This Amending Agreement to the Share Purchase Agreement dated 10/02/2019 (the "Amending Agreement") by and among CannaPharmaRx Canada Corp. '(the "Purchaser"), CannaPharmaRx, Inc. (the "Purchaser Parent") and Sunniva Inc. (the "Vendor"). WHEREAS, the Purchaser, the Purchaser Parent and the Vendor entered into the Share Purchase Agreement
August 14, 2019	10-Q	CPMD / Cannapharmarx Inc. 10-Q - Quarterly Report - FORM 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: June 30, 2019 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State or other jurisdiction of incorporation) (IRS Employer ID No.) 3600 888
August 14, 2019	10-K/A	CPMD / Cannapharmarx Inc. 10-K/A - Annual Report - FORM10-K AMENDMENT Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 000-27055 CANNAPHARMA
June 12, 2019	EX-10.5	Agreement dated May 7, 2019 between KannaREIT, Inc. and Cannapharmarx, Inc. Exhibit 10.5 This Heads of Agreement (this “HOA”) is dated 07 May 2019. KANNAREIT INC. (hereinafter referred to as “KannaREIT”) OF THE FIRST PART, - and - CANNAPHARMARX INC. (hereinafter referred to as "CPRX") OF THE SECOND PART. HEADS OF AGREEMENT WHEREAS: i. CPRX is a corporation incorporated pursuant to the laws of the State of Delaware; ii. KannaREIT is a corporation incorporated pursuant to t
June 12, 2019	EX-10.4	Securities Purchases Agreement dated June 11, 2019 by and between Cannapharmarx Canada Corp., Cannapharmarx, Inc., as Purchasers and Sunniva, Inc., as Seller Exhibit 10.4 CannaPharmaRx CANADA CORP. - and – CannaPharmaRx, INC. - and – SHARE PURCHASE AGREEMENT June 11, 2019 TABLE OF CONTENTS Article 1 INTERPRETATION Section 1.1 Defined Terms. 1 Section 1.2 Gender and Number. 7 Section 1.3 Headings, etc. 8 Section 1.4 Currency. 8 Section 1.5 Certain Phrases, etc. 8 Section 1.6 Knowledge. 8 Section 1.7 References to Persons and Agreements. 8 Section 1.8 St
June 12, 2019	EX-99.5	SUNNIVA INC. AGREES TO SELL ITS OKANAGAN FALLS PROPERTY TO CANNAPHARMARX, INC. FOR CAD $20 MILLION Transaction is subject to financial audit and satisfaction of other conditions Exhibit 99.5 For Immediate Release June 12, 2019 SUNNIVA INC. AGREES TO SELL ITS OKANAGAN FALLS PROPERTY TO CANNAPHARMARX, INC. FOR CAD $20 MILLION Transaction is subject to financial audit and satisfaction of other conditions VANCOUVER, BC – June 12, 2019 – Sunniva Inc. (“Sunniva”) (CSE:SNN, OTCQB:SNNVF) and CannaPharmaRx, Inc. (“CannaPharmaRx”) (OTC Pink: CPMD) are pleased to announce that they
June 12, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2019 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission Fil
May 15, 2019	EX-10.3	Lease Agreement – 3600 888 3St SW, Calgary, Alberta, Canada Exhibit 10.3 COMMERCIAL LEASE AGREEMENT THIS LEASE (this "Lease") dated this 14th day of March, 2019. BETWEEN: Persta Resources Inc (Referred to as the "Landlord") of THE FIRST PART AND CannaPharmaRx Inc (Tenant(s) referred to in this Agreement either individually or collectively as the "Tenant") of THE SECOND PART IN CONSIDERATION OF the Landlord leasing certain premises to the Tenant, the Tenant
May 15, 2019	10-Q	CPMD / Cannapharmarx Inc. 10-Q Quarterly Report FORM 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2019 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) Suite 3
April 30, 2019	DEF 14A	CPMD / Cannapharmarx Inc. DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [ ] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [] Definitive Additional Materials [] Soliciting Material under Rule 14a-12 Cannapharmarx, Inc.
April 26, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2019 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission Fi
April 3, 2019	EX-10.4	Form of Registration Rights Agreement Exhibit 10.4 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement ("Agreement"), dated this day of 2018, by and between Cannapharmarx, Inc., a Delaware corporation, (the "Company") and , ("Holder"), whose address is , who hereby agree as follows: R E C I T A L S WHEREAS, Holder is the beneficial owner of shares of the Company’s Common Stock (the "Shares; and WHEREAS, Holder has
April 3, 2019	EX-10.5	Form of Convertible Debenture Exhibit 10.5 THIS DEBENTURE, AND ANY SHARES ACQUIRED UPON CONVERSION HEREOF, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE "ACT") OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (B) AN
April 3, 2019	EX-21.1	List of Subsidiaries EXHIBIT 21.1 LIST OF SUBSIDIARIES Alternative Medical Solutions, Inc.,, a Canadian corporation
April 3, 2019	10-K	CPMD / Cannapharmarx Inc. FORM 10-K (Annual Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 000-27055 CANNAPHARMARX
April 1, 2019	NT 10-K	CPMD / Cannapharmarx Inc. NOTICE OF LATE FILING OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 000-27055 CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2018 o
February 28, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2019 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission
February 28, 2019	EX-99.1	CANNAPHARMARX ANNOUNCES THE ACQUISITION OF A MINORITY INTREST IN GREAT NOTHERN CANNABIS, A CANADIAN CANNABIS PRODUCER, AND THE APPOINTMENT OF DOMINIC COLVIN AS CEO AND CHARIMAN OF THE BOARD Company Continues to acquire Cannabis Grow Capacity in Canad Exhibit 99.1 CANNAPHARMARX ANNOUNCES THE ACQUISITION OF A MINORITY INTREST IN GREAT NOTHERN CANNABIS, A CANADIAN CANNABIS PRODUCER, AND THE APPOINTMENT OF DOMINIC COLVIN AS CEO AND CHARIMAN OF THE BOARD Company Continues to acquire Cannabis Grow Capacity in Canada IRVINE, CA—[February 26, 2019]—CannaPharmaRx, Inc. (OTC Pink Sheets: “CPMD”) announced today it has completed the acquisition of a mino
February 14, 2019	8-K/A	Regulation FD Disclosure, Change in Shell Company Status, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2018 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorp
January 30, 2019	8-K	Unregistered Sales of Equity Securities U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2019 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission
January 7, 2019	8-K/A	Regulation FD Disclosure, Change in Shell Company Status, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2018 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commissi
January 7, 2019	EX-99.7	CANNAPHARMARX ANNOUNCES THE ACQUISITION OF ALTERNATIVE MEDICAL SOLUTIONS Company Continues its Efforts to Re-Enter Cannabis Space Exhibit 99.7 For Immediate Release January 8, 2019 CANNAPHARMARX ANNOUNCES THE ACQUISITION OF ALTERNATIVE MEDICAL SOLUTIONS Company Continues its Efforts to Re-Enter Cannabis Space IRVINE, CA—[January 8, 2019]—Cannapharmarx, Inc. (OTC Pink Sheets: “CPMD”) announced today it has completed the acquisition of Alternative Medical Solutions, Inc., (“AMS”), an Ontario, Canada corporation. Under the term
December 18, 2018	DEF 14C	CPMD / Cannapharmarx Inc. DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [] Preliminary Information Statement [] Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement CANNAPHARMARX, INC. (Name of Reg
December 6, 2018	PRE 14C	CPMD / Cannapharmarx Inc. FORM PRE14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [] Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) [] Definitive Information Statement CANNAPHARMARX, INC. (Name of Reg
November 21, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2018 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission
November 21, 2018	EX-10.3	Securities Purchase Agreement between Alternative Medical Solutions Inc. and Shareholders thereof and CannaPharmaRX, Inc. and Hanover CPMD Acquisition Corp. dated 11/19/18 Exhibit 10.3 SECURITIES PURCHASE AGREEMENT THIS AGREEMENT is dated the 19th day of November, 2018 BETWEEN: ALTERNATIVE MEDICAL SOLUTIONS INC., a company existing under the laws of the Province of Ontario (the “Corporation”) - and - ALL OF THE SHAREHOLDERS OF THE CORPORATION, AS SET FORTH IN SCHEDULE A TO THIS AGREEMENT (collectively, the “Vendors”) - and - CANNAPHARMARX, INC., a company existing u
November 13, 2018	10-Q	CPMD / Cannapharmarx Inc. QUARTERLY REPORT (Quarterly Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: September 30, 2018 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 2 P
September 14, 2018	10-Q	CPMD / Cannapharmarx Inc. FORM 10-Q (Quarterly Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: September 30, 2017 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 2 P
September 14, 2018	10-Q	CPMD / Cannapharmarx Inc. FORM 10-Q (Quarterly Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2016 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 2 Park
September 14, 2018	10-Q	CPMD / Cannapharmarx Inc. FORM 10-Q (Quarterly Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: June 30, 2017 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 2 Park P
September 14, 2018	10-Q	CPMD / Cannapharmarx Inc. QUARTERLY REPORT (Quarterly Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2017 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 2 Park
September 14, 2018	10-K	CPMD / Cannapharmarx Inc. FORM 10-K (Annual Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 000-27055 CANNAPHARMARX
September 14, 2018	10-Q	CPMD / Cannapharmarx Inc. FORM 10-Q FOR JUNE 30, 2018 (Quarterly Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: June 30, 2018 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 2 Park P
September 14, 2018	10-Q	CPMD / Cannapharmarx Inc. FORM 10-Q (Quarterly Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: September 30, 2016 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 2 P
September 14, 2018	10-K	CPMD / Cannapharmarx Inc. FORM 10-K (Annual Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 000-27055 CANNAPHARMARX
September 14, 2018	10-Q	CPMD / Cannapharmarx Inc. FORM 10-Q FOR MARCH 31, 2018 (Quarterly Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2018 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 2 Park
September 14, 2018	10-Q	CPMD / Cannapharmarx Inc. FORM10-Q (Quarterly Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: June 30, 2016 Commission File Number: 000-27055 CANNAPHARMARX, INC. (Exact name of small business issuer as specified in its charter) Delaware 27-4635140 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 2 Park P
September 11, 2018	10-K	CPMD / Cannapharmarx Inc. FORM 10-K FOR 2015 (Annual Report) Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number: 000-27055 CANNAPHARMARX
June 15, 2018	EX-16.1	Letter from KLJ & Associates, LLP Exhibit 16.1 June 14, 2018 United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 We have read the statements of CannaPharmaRX, Inc., pertaining to our firm included under Item 4.01 of Form 8-K dated April 20, 2018 and agree with such statements as they pertain to our firm. Sincerely, /s/ KLJ & Associates, LLP
June 15, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2018 Cannapharmarx, Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-27055 24-4635140 (State or other jurisdiction of incorporation) (Commission Fi
April 13, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 12, 2018 CANNAPHARMARX, Inc.
June 1, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 11, 2016 CANNAPHARMARX, Inc.
June 1, 2016	EX-99.1	EXHIBIT 99.1 EXHIBIT 99.1 January 11, 2016 Mr. Jim Smeeding Mr. Robert Liess Mr. David Pohl Mr. Steve Rule Mr. Elie Khalifie Canna Pharma Rx 1 Collins Drive; Suite 100 Carneys Point NJ 08069 Dear CannaPharma Rx Board of Directors, Please accept my resignation from the board of directors of CannaPharma Rx. While I wish the remaining team the best of luck, several circumstances have changed which effect my abili
April 15, 2016	EX-99	Exhibit 99.5 Exhibit 99.5 The undersigned, Elie Khalife, hereby resigns as a Director of CannaPharmaRx, Inc. (the "Company") effective the date below. Such resignation is voluntary and without dispute or disagreement as to the business, accounting, financial, and regulatory matters of the Company. I confirm that the Company owes me no compensation, options or warrants, or insurance benefits. Effective the 6th
April 15, 2016	EX-99	Exhibit 99.3 Exhibit 99.3 To: Jim Smeeding, CannaPharmaRx Board Members and Associates From: David Pohl Date: April 5, 2016 Subject: Resignation from CPMD Board Dear CannaPharmaRx Board Members and Associates, This letter is to inform you that I am resigning as a member of CannaPharmaRx Board of Directors, effective immediately. It has been my pleasure to serve on the board since last year. However, I feel I h
April 15, 2016	EX-99	Exhibit 99.1 Exhibit 99.1 April 5, 2016 Mr. Robert Liess Mr. David Pohl Mr. Steve Rule Mr. Elie Khalifie Mr. Gary Herick Michael Littman Corporate Counsel Canna Pharma Rx 4029 Gilbert Avenue Dallas, Texas 75219 Dear CannaPharma Rx Board of Directors,Officers, and to whom this may concern - Please accept my resignation as Interim President of CannaPharma Rx and EVP of Professional Services. I have not received
April 15, 2016	EX-99	Exhibit 99.4 Exhibit 99.4 April 5, 2016 To: The CannaPharmaRx Board of Directors From: Steve Rule Re: Resignation Letter Dear CPMD Board Members: After careful thought and consideration, I am tendering my resignation from the CannaPharmaRx Board effective immediately. I was brought on to the CPMD Board to provide expertise in the area of acquiring existing specialty and compounding pharmacies, as well as negot
April 15, 2016	EX-99	Exhibit 99.6 Exhibit 99.6 "The undersigned, Robert M. Liess, hereby resigns as an Officer (and/or) Director of CannaPharmaRx, (the "company") effective the date below. Such resignation is voluntary and without dispute or disagreement as to the business, accounting, financial, and regulatory matters of the company. I confirm that the Company owes me no compensation, options or warrants, or insurance benefits. E
April 15, 2016	EX-99	Exhibit 99.2 Exhibit 99.2 Apr 5 2016 To Whom it may Concern, please accept this as my formal resignation as VP of product development for CannaPharmaRx, INC. The reason for my resignation is to have more time for my family, as Olivia and I are expecting next month. I would like to take this opportunity to remind CannaPharmaRx that I have not been receiving my salary or benefits since October 3rd, 2015. This am
April 15, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 6, 2016 CANNAPHARMARX, Inc.
March 30, 2016	NT 10-K	Cannapharmarx 0-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-27055 (Check one): x Form 10-K oForm 20-F oForm 11-K oForm 10-Q o Form N-SAR oForm N-CSR For Period Ended: December 31, 2015 oTransition Report on Form 10-K oTransition Report on Form 20-F oTransition Report on Form 11-K oTransition Report on Form 10-Q oTransition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
January 13, 2016	EX-99.1	EX-99.1 Exhibit 99.1
January 13, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 18, 2015 CANNAPHARMARX, Inc.
January 13, 2016	EX-99.2	EX-99.2 Exhibit 99.2
November 13, 2015	10-Q	Cannapharmarx 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 6, 2015	8-K/A	Submission of Matters to a Vote of Security Holders CannaPharmaRx, Inc. (Form: 8-K/A) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 6, 2015 CannaPharmaRx, Inc. (Exact name of registrant as specified in its charter) Delaware 000-27055 27-4635140 (State o
August 31, 2015	8-K	Submission of Matters to a Vote of Security Holders CannaPharmaRx, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 28, 2015 CannaPharmaRx, Inc. (Exact name of registrant as specified in its charter) Delaware 000-27055 27-4635140 (State or other jurisdiction (
August 24, 2015	DEFA14A	Cannapharmarx DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitt
August 12, 2015	EX-10.1	Proposal: Placement Agreement The Alternative Investment Store, division of Benjamin & Jerold Brokerage I, LLC. CannaPharmaRX, Inc EXHIBIT 10.1 Proposal: Placement Agreement The Alternative Investment Store, division of Benjamin & Jerold Brokerage I, LLC. for CannaPharmaRX, Inc Prepared for: Gerald Crocker CEO & Gary Herick Director of Finance \| CannaPharmaRX, Inc. One Collins Drive, Salem Business Center, Carneys Point, NJ 08069-3640 \| Phone: 720.939.1133 \| Email: [email protected] Prepared by: Troy R Vanderburg Chief Ex
August 12, 2015	EX-10.2	CONFIDENTIAL SETTLEMENT AND RELEASE OF CLAIMS AGREEMENT EXHIBIT 10.2 CONFIDENTIAL SETTLEMENT AND RELEASE OF CLAIMS AGREEMENT THIS CONFIDENTIAL SETTLEMENT AND RELEASE OF CLAIMS AGREEMENT (?AGREEMENT?), effective on the last date executed below, is entered into between CANNAPHARMARX, INC., a Delaware corporation (?CPRx?), on behalf of itself, its officers, directors, owners, shareholders, employees, attorneys, representatives and agents (in their individ
August 12, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-27055 CANNAPHARMA
August 12, 2015	EX-10.3	CONSULTING AGREEMENT EXHIBIT 10.3 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is made this 26th day of June, 2015, between Gary Herick (?Herick?) and CannaPharmaRx, Inc. (?CannaPharmaRx?), a Delaware corporation. WHEREAS, CannaPharmaRx desires to retain the services of Herick to provide the services delineated in this Agreement. WHEREAS, Herick is agreeable to providing said services on the terms
July 21, 2015	SC 13D	CPMD / Cannapharmarx Inc. / SMEEDING JAMES E - SC 13D - JAMES SMEEDING Activist Investment SC 13D - James Smeeding UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 21, 2015	EX-2.1	AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER EX-2.1 EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This Amended and Restated Agreement and Plan of Merger (this “AGREEMENT”) is made and entered into as of April 21, 2015 (the “EFFECTIVE DATE”), by and among CannaPharmaRx, Inc., a Delaware corporation (“CANNA DELAWARE”), CannaPharmaRX, Inc., a Colorado corporation (“CPHR”), and CPHR Acquisition Corp., a Delaware corporation and a
July 17, 2015	DEF 14A	Cannapharmarx DEFINITIVE PROXY STATEMENT Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 9, 2015	EX-2.1	AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER EX-2.1 EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This Amended and Restated Agreement and Plan of Merger (this “AGREEMENT”) is made and entered into as of April 21, 2015 (the “EFFECTIVE DATE”), by and among CannaPharmaRx, Inc., a Delaware corporation (“CANNA DELAWARE”), CannaPharmaRX, Inc., a Colorado corporation (“CPHR”), and CPHR Acquisition Corp., a Delaware corporation and a
July 9, 2015	SC 13D	CPMD / Cannapharmarx Inc. / SHERWOOD MATHEW D - SC13D - MATHEW SHERWOOD Activist Investment SC13D - Mathew Sherwood UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 7, 2015	8-K	Other Events CannaPharmaRx, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 1, 2015 CannaPharmaRx, Inc. (Exact name of registrant as specified in its charter) Delaware 000-27055 27-4635140 (State or other jurisdiction (Com
July 2, 2015	EX-2.1	AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER EX-2.1 EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This Amended and Restated Agreement and Plan of Merger (this “AGREEMENT”) is made and entered into as of April 21, 2015 (the “EFFECTIVE DATE”), by and among CannaPharmaRx, Inc., a Delaware corporation (“CANNA DELAWARE”), CannaPharmaRX, Inc., a Colorado corporation (“CPHR”), and CPHR Acquisition Corp., a Delaware corporation and a
July 2, 2015	8-K	Changes in Control of Registrant, Unregistered Sales of Equity Securities CannaPharmaRx, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 29, 2015 CannaPharmaRx, Inc. (Exact name of registrant as specified in its charter) Delaware 000-27055 27-4635140 (State or other jurisdiction (Co
July 2, 2015	SC 13D	CPMD / Cannapharmarx Inc. / CROCKER GERALD EUGENE JR - SC 13D - GERRY CROCKER Activist Investment SC 13D - Gerry Crocker UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 2, 2015	SC 13D	CPMD / Cannapharmarx Inc. / Herick Gary J - SC 13D - GARY HERICK Activist Investment SC 13D - Gary Herick UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 2, 2015	EX-2.1	AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER EX-2.1 EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This Amended and Restated Agreement and Plan of Merger (this “AGREEMENT”) is made and entered into as of April 21, 2015 (the “EFFECTIVE DATE”), by and among CannaPharmaRx, Inc., a Delaware corporation (“CANNA DELAWARE”), CannaPharmaRX, Inc., a Colorado corporation (“CPHR”), and CPHR Acquisition Corp., a Delaware corporation and a
June 30, 2015	EX-10.1	AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER EX-10.1 EX-10.1 EXHIBIT 10.1 (EXECUTION VERSION) AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This Amended and Restated Agreement and Plan of Merger (this "AGREEMENT") is made and entered into as of April 21, 2015 (the "EFFECTIVE DATE"), by and among CannaPharmaRx, Inc., a Delaware corporation ("CANNA DELAWARE"), CannaPharmaRX, Inc., a Colorado corporation ("CPHR"), and CPHR Acquisition Corp.
June 30, 2015	EX-10.1	AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER EX-10.1 EX-10.1 EXHIBIT 10.1 (EXECUTION VERSION) AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This Amended and Restated Agreement and Plan of Merger (this "AGREEMENT") is made and entered into as of April 21, 2015 (the "EFFECTIVE DATE"), by and among CannaPharmaRx, Inc., a Delaware corporation ("CANNA DELAWARE"), CannaPharmaRX, Inc., a Colorado corporation ("CPHR"), and CPHR Acquisition Corp.
June 30, 2015	EX-10.1	AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER EX-10.1 EX-10.1 EXHIBIT 10.1 (EXECUTION VERSION) AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This Amended and Restated Agreement and Plan of Merger (this "AGREEMENT") is made and entered into as of April 21, 2015 (the "EFFECTIVE DATE"), by and among CannaPharmaRx, Inc., a Delaware corporation ("CANNA DELAWARE"), CannaPharmaRX, Inc., a Colorado corporation ("CPHR"), and CPHR Acquisition Corp.
May 28, 2015	8-K/A	Cannapharmarx LIVE FILING (Current Report/Significant Event) CannaPharmaRx, Inc. (Form: 8-K/A) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 30, 2015 CannaPharmaRx, Inc. (Exact name of registrant as specified in its charter) Delaware 000-27055 27-4635140 (State or
May 28, 2015	EX-10.2	EX-10.2 EX-10.2
May 28, 2015	EX-10.1	CONFIDENTIAL SETTLEMENT AND RELEASE OF CLAIMS AGREEMENT EX-10.1 EXHIBIT 10.1 CONFIDENTIAL SETTLEMENT AND RELEASE OF CLAIMS AGREEMENT THIS CONFIDENTIAL SETTLEMENT AND RELEASE OF CLAIMS AGREEMENT (?AGREEMENT?), effective on the last date executed below, is entered into between CANNAPHARMARX, INC., a Delaware Corporation (?CPRx?), on behalf of itself, its officers, directors (including GARY HERICK (?Herick?), GERALD CROCKER (?Crocker?), JAMES SMEEDING (?S
May 27, 2015	8-K	Cannapharmarx LIVE FILING (Current Report/Significant Event) CannaPharmaRx, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2015 CannaPharmaRx, Inc. (Exact name of registrant as specified in its charter) Delaware 000-27055 27-4635140 (State or other jurisdiction (Com
May 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 000-27055 CANNAPHARM
May 14, 2015	EX-10.2	Form of Exchange Agreement, Consent and Representations between-exchange shares of CannaPharmaRX, Inc. (DE) to shareholders of CannaPharmaRX, Inc. (CO) (undated) Exhibit 10.2 EXCHANGE AGREEMENT, CONSENT, AND REPRESENTATIONS Ladies and Gentlemen: I understand that CannaPharmaRx, Inc. (the ?Company?), a Delaware corporation, is offering to exchange restricted Common Shares for common shares of CannaPharmaRx, Inc. (?CPI-CO?), a Colorado corporation, to the shareholders of CPI-CO pursuant to a Plan of Merger (?Plan of Merger?) attached hereto as Exhibit A and
April 29, 2015	8-K	Unregistered Sales of Equity Securities CannaPharmaRx, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 23, 2015 CannaPharmaRx, Inc. (Exact name of registrant as specified in its charter) Delaware 000-27055 27-4635140 (State or other jurisdiction (C
April 24, 2015	8-K	Cannapharmarx LIVE FILING (Current Report/Significant Event) CannaPharmaRx, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 21, 2015 CannaPharmaRx, Inc. (Exact name of registrant as specified in its charter) Delaware 000-27055 27-4635140 (State or other jurisdiction (C
April 24, 2015	EX-2.1	Amended and Restated Agreement and Plan of Merger between CannaPharmaRx, Inc. (DE), CannaPharmaRX, Inc. (CO) and CPHR Acquisition Corp. (subsidiary of Canna DE) dated 4/21/15 EX-2.1 EXHIBIT 2.1 (EXECUTION VERSION) AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This Amended and Restated Agreement and Plan of Merger (this ?AGREEMENT?) is made and entered into as of April 21, 2015 (the ?EFFECTIVE DATE?), by and among CannaPharmaRx, Inc., a Delaware corporation (?CANNA DELAWARE?), CannaPharmaRX, Inc., a Colorado corporation (?CPHR?), and CPHR Acquisition Corp., a Delawa
April 24, 2015	EX-99.1	CANNAPHARMARX’S BOARD OF DIRECTORS APPROVES PLAN OF MERGER EX-99.1
April 6, 2015	EX-99.1	April 1, 2015 EX-99.1 April 1, 2015 CANNAPHARMARX ANNOUNCES THE APPOINTMENT OF THREE NEW MEMBERS TO ITS BOARD OF DIRECTORS Carneys Point, NJ April 1, 2015CannaPharmaRx, Inc. (OTCQB: CPMD), a New Jersey-based pharmaceutical company, announced today that it has expanded its Board of Directors effective today with the express intent of bringing new and diverse skill sets that will complement its current Boards
April 6, 2015	8-K	Cannapharmarx LIVE FILING (Current Report/Significant Event) CannaPharmaRx, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 1, 2015 CannaPharmaRx, Inc. (Exact name of registrant as specified in its charter) Delaware 000-27055 27-4635140 (State or other jurisdiction (Co
April 3, 2015	EX-10.1	Confidential Settlement and Release of Claims Agreement between CannaPharmaRX, Inc. and Gary Herick, Gerald Crocker, James Smeeding, Matthew Sherwood and Robert Liess and Gary M. Cohen dated 3/30/15 EX-10.1 Exhibit 10.1 *** Indicates that a portion of the exhibit has been omitted based on a request for confidential treatment submitted to the Securities and Exchange Commission. The omitted portions have been filed separately with the Commission. CONFIDENTIAL SETTLEMENT AND RELEASE OF CLAIMS AGREEMENT THIS CONFIDENTIAL SETTLEMENT AND RELEASE OF CLAIMS AGREEMENT (?AGREEMENT?), effective on the l
April 3, 2015	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2015 CANNAPHARMARX, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-27055 27-4635140 (State or Other Jurisdiction of Incorporation) (Commission
March 31, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 OR ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO. 000-27055 CANNAPHARMARX, INC. (EXACT NAME OF REGIS
March 31, 2015	EX-10.2	Form of Exchange Agreement and Representations-exchange shares of CannaPharmaRX, Inc. (DE) to shareholders of CannaPharmaRX, Inc. (CO) (undated) Exhibit 10.2 EXCHANGE AGREEMENT AND REPRESENTATIONS Gentlemen: I understand that CannaPharmaRx, Inc. (the ?Company?), a Delaware corporation, is offering to exchange restricted Common Shares for common shares of CannaPharmaRx, Inc. (?CPI-CO?), a Colorado corporation, to the shareholders of CPI-CO. I hereby offer to exchange all of my Shares of CPI-CO, as shown on the transfer records of CPI-CO for

CPMD / CannaPharmaRX, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)